Shock therapy? giving testosterone to fight prostate cancer

NCT ID NCT06922318

Summary

This study is testing a two-step treatment for men whose prostate cancer has spread and stopped responding to standard hormone-blocking therapies. First, patients receive high-dose testosterone combined with an experimental drug called ZEN-3694. If the cancer progresses, they then switch to a different combination of enzalutamide (a standard prostate cancer drug) plus ZEN-3694. The goal is to see if this sequence can better control the cancer and delay its growth compared to past treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21205, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.